Demir Eksikliği Anemisi İlişkili Trombositoz;Maskeli Myeloproliferatif Hastalık Olabilir mi?

Amaç: Trombositoz hematoloji bölümünde istenen konsültasyonların sık nedenleri arasındadır. Trombositoz etyolojisi primer ve sekonder olarak sınıflandırılır. Primer trombositoz myeloproliferatif hastalık nedeni ile klonal bir üretim sonucu iken, sekonder trombositoz altta yatan reaktif bir neden sonucunda gelişir ve neden ortadan kalktığı zaman düzelir. Demir eksikliği anemisi (DEA) reaktif trombositozun sık nedenidir. Bu çalışmada amaç DEA ilişkili trombositoz nedeni ile başvuran hastalarda maskelenmiş bir myeloprolif hastalığın varlığını araştırmaktır. Materyal ve Metot: DEA ve trombositoz nedeni ile hematoloji polikliniğine başvuran 50 hasta çalışmaya dahil edilmiştir. Enfeksiyon, yakın zamanda geçirilmiş cerrahi, malignite, inflamatuvar hastalıklar, aspleni gibi diğer reaktif trombositoz nedenleri ve gebelik çalışma dışı bırakılmıştır. Tüm hastalara DEA tedavisinde oral veya intravenöz yol ile demir replasmanı uygulanmıştır. Tedavi öncesinde ve 1. ayında anemi ve trombosit düzeyleri kontrol edilmiştir. Ayrıca hastalarda myeloproliferatif hastalık araştırmasına yönelik JAK2 V617F (JAK2) mutasyonu taraması yapılmıştır. Bulgular: Demir tedavisini takiben hemoglobin (Hb) ve ferritin düzeylerinde tedavini 1. ayında anlamlı yükselme izlenmiştir (p

Thrombocytosis Associated with Iron Deficiency Anemia;Is It A Masked Myeloproliferative Disorder?

Objectives: Thrombocytosis is a frequent reason for hematological consultation. The etiology ofthrombocytosis is classified as primary and secondary. While primary is result of clonal expansion dueto myeloproliferative disorders (MPD), secondary thrombocytosis occurs due to a reactive state andregresses when that is resolved. Iron deficiency (IDA) is a frequent cause of reactive thrombocytosis inoutpatients. The aim of this study was to investigate whether IDA and thrombocytosis mask a MPD inpatients presenting with these complaints.Materials and Methods: This prospective study included 50 patients who were admitted to ourhematology clinic with thrombocytosis and IDA. Causes of reactive thrombocytosis such as infections,surgery, malignancies, inflammatory diseases, asplenia, and pregnancy were excluded. All patientsreceived oral or intravenous(iv) iron replacement as anemia treatment. Anemia and thrombocyte (PLT)count were measured and recorded initially and at the end of first month. JAK2 V617F (JAK2) mutationwas also checked due to MPD investigation.Results: Hemoglobin (Hb) and ferritin levels increased in the first month of treatment (p

PDF

___

1. Kasper CK, Whissell YE, Wallerstein RO. Clinical aspects of iron deficiency. JAMA 1965;191:359– 63.
2. Schloesser LL, Kipp MA, Wenzel FJ. Thrombocytosis in iron deficiency anemia. J Lab Clin Med 1965;66:107–14.
3. Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: Analysis of 732 patients with an elevated thrombocyte count. J Intern Med 1999;245:295–300.
4. Kadikoylu G, Yavasoglu I, Bolaman Z, Senturk T. Thrombocyte parameters in women with iron deficiency anemia. J Natl Med Assoc 2006;98:398–402.
5. Dan K. Thrombocytosis in iron deficiency anemia. Intern Med 2005;44:1025–26.
6. Aydogan T, Kanbay M, Alici O, Kosar A. Incidence and etiology of thrombocytosis in an adult Turkish population. Thrombocytes 2006;17:328–31.
7. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO vitamin and mineral nutrition information system, 1993‐2005. Public Health Nutr. 2009;12:444–54.
8. Kassebaum NJ, Jasrasaria R, Naghavi M. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123:615.
9. Estadella J, Villamarín L, Feliu A, Perelló J ,Calaf J.Characterization of the population with severe iron deficiency anemia at risk of requiring intravenous iron supplementation. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2018:224;41‐4.
10. Saydam BK, Genc RE, Sarac F, Turfan EC. Prevalence of anemia and related factors among women in Turkey. Pak J Med Sci. 2017; 33: 433–38.
11. Xu X, Zhang Q, Luo J, Xing S, Li Q, Krantz SB. JAK2 (V617F): Prevalence in a large Chinese hospital population. Blood 2007; 109: 339‐42.
12. Tevet M, Ionescu R, Dragan C, Lupu AR. Influence of the JAK2 V617F mutationand inherited thrombophilia on the thrombotic risk among patients with myeloproliferative disorders. Maedica (Buchar) 2015; 10: 27‐32.
13. Tefferi A, Ho TC, Ahmann GJ Katzmann JA, Greipp PR. Plasma interleukin‐6 and C‐reactive protein levels in reactive versus clonal thrombocytosis. Am J Med 1994:97;374–78.
14. Alexandrakis MG, Passam FH, Moschandrea IA, Christophoridou AV, Pappa CA, Coulocheri SA et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer‐ related thrombocytosis. Am J Clin 2003:26; 135–40.
15. Yoshida S, Kohro S, Yamakage M Nakayama M, Namiki A. A case of suspected pulmonary thrombosis in a patient with reactive thrombocytemia who underwent liver subsegmentectomy. Masui.2003;52:1320‐22.
16. Mishra SB, Bhoyer J, Gurjar M, Muzaffar N, Verma A. Deep vein thrombosis of upper extremities due to reactive thrombocytosis in septic patients. Indian J Crit Care Med. 2014;18:540‐42.
17. Evstatiev R. Iron deficiency, thrombocytosis and thromboembolism. Wien Med Wochenschr. 2016;166:437‐46.
18. Hengeveld PJ, Hazenberg MD, Biezeveld MH, Raphael MF. Risk of thrombosis is a reactive thrombocytosis. Ned Tijdschr Geneeskd. 2018;162: 2697.